
News|Videos|November 6, 2024
Insulin Icodec Represents A Promising Option for Managing Diabetes, Improving Quality of Life
Author(s)Killian Meara
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how insulin icodec differs from existing daily basal insulins and key things pharmacists need to know about the medication.
Advertisement
Advertisement
In the United States, about 38 million people have diabetes and more than 1 in 3 Americans have prediabetes but are unaware of it.1 The prevalence of the disease in the country is also expected to continue increasing, with some research estimating that more than 54 million people will have diabetes by 2030.2 As diabetes represents a major health crisis in the US, increasing awareness and improving disease management are crucial.
Related to this article

In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.

Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.

In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.

In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.

Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.

Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.

Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.
Advertisement
Advertisement

